SARS-CoV-2 Spread Dynamics in Italy: The Calabria Experience.


Journal

Reviews on recent clinical trials
ISSN: 1876-1038
Titre abrégé: Rev Recent Clin Trials
Pays: United Arab Emirates
ID NLM: 101270873

Informations de publication

Date de publication:
2021
Historique:
received: 29 10 2020
revised: 03 02 2021
accepted: 23 02 2021
pubmed: 3 4 2021
medline: 18 8 2021
entrez: 2 4 2021
Statut: ppublish

Résumé

The first case of infection by SARS-CoV-2 (i.e., COVID-19) has been officially recorded by the Italian National Health Service on February 21st, 2020. Lombardy was the first Italian region to be affected by the pandemic. Subsequently, the entire Northern part of Italy recorded a high number of cases, while the South was hit following the migratory waves. On March 8th, the Italian Government has issued a decree that imposed a total lockdown, defining it as a state of isolation and restricting access in Lombardy and the other 14 provinces of Northern Italy. We analyzed the virus trend in the period between February 24th and September 8th, 2020, focusing on Calabria, with regards to the following items: new positives, change of total positives, and total cases. Furthermore, we included other information, such as the incubation period, symptom resolution period, quarantine period. On March 27th, the epidemic curve spiked with 101 new positive cases validating the hypothesis that this abnormal event was related to the displacement of non-residents people, living in the Northern part of Italy, to the home regions in the South. The epidemic curve showed a decreasing trend in the period after lockdown, proving the effectiveness of this measure. From the end of the lockdown May 04th to September 8th, the registered trend was -94.51%. A negative growth rate indicates that the number of new positive cases is lower than the number of healed patients. This study describes the effectiveness of the Italian Government policy, particularly the role of lockdown, for the containment of SARS-CoV-2 contagion in Calabria, a region with a low SARS-CoV-2 infection rate within the registered period.

Identifiants

pubmed: 33797377
pii: RRCT-EPUB-115140
doi: 10.2174/1574887116666210401124945
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

309-315

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Ludovico Abenavoli (L)

Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro , Italy.

Pietro Cinaglia (P)

Department of Surgical and Medical Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.

Anna Caterina Procopio (AC)

Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro , Italy.

Raffaele Serra (R)

Department of Surgical and Medical Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.

Isabella Aquila (I)

Department of Surgical and Medical Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.

Christian Zanza (C)

Department of Anesthesia and Critical Care Medicine, SS. Antonio and Biagio and Cesare Arrigo Hospital, 15121 Alessandria, Italy.

Yaroslava Longhitano (Y)

Department of Anesthesia and Critical Care Medicine, SS. Antonio and Biagio and Cesare Arrigo Hospital, 15121 Alessandria, Italy.

Marco Artico (M)

Department of Sensory Organs, Sapienza University of Rome Policlinico Umberto I, 00155 Rome, Italy.

Tiziana Larussa (T)

Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro , Italy.

Luigi Boccuto (L)

Clemson University, Clemson, SC, 29634, United States.

Pietrantonio Ricci (P)

Department of Surgical and Medical Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.

Francesco Luzza (F)

Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro , Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH